ZL 6201
Alternative Names: ZL-6201Latest Information Update: 24 Feb 2026
At a glance
- Originator ZAI Lab
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Sarcoma; Solid tumours
Most Recent Events
- 12 Feb 2026 Phase-I clinical trials in Sarcoma (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (Parenteral) (NCT07374848)
- 12 Feb 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (Parenteral) (NCT07374848)
- 31 Jan 2026 US FDA approves IND application for a global phase I study in patients with sarcoma and potentially other LRRC15-positive solid tumours